Genmab Daratumumab

Genmab Has Obtained FDA Fast Track Designation in Double Refractory Multiple Myeloma
Apr 4, 2013
Biotechnology company Genmab has obtained FDA fast track designation in double refractory multiple myeloma for daratumumab. As per the designation, the human CD38 monoclonal antibody Daratumumab is suitable for multiple myeloma patients ...

Tags: Genmab Daratumumab, FDA, Fast Track Designation